Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population
NCT03580070 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 140
Last updated 2020-02-17
Summary
Retrospective observational comparative and multicentric study of the microenvironment of HPV-induced head and neck cancers, with comparison between West Indies and Metropolitan populations, and therapeutic implications. This assessment is carried out by in situ multiparametric study with multiple immunofluorescence staining for cluster of differentiation 3, cluster of differentiation 4, cluster of differentiation 8, PROGRAMMED DEATH-1, PROGRAMMED DEATH-L1, PROGRAMMED DEATH-L2, cytokeratin and cluster of differentiation 68 and automated reading. HPV genotypes will be characterized. Learning these techniques will allow me to promote them in West Indies on my way back, and they may be applicable to other HPV-induced cancers.
Conditions
- Immunotherapy
Interventions
- BIOLOGICAL
-
Immunotherapy
Patients with primitive head and neck squamous cells carcinoma diagnosed on surgical resection or biopsic sample, between 2008 and 2015. They were included when expressing p16 as assessed by immunochemistry and positive HPV DNA by in situ hybridation or positive HPV PCR
Sponsors & Collaborators
-
European Georges Pompidou Hospital
collaborator OTHER -
University Hospital Center of Martinique
lead OTHER
Principal Investigators
-
Vincent MOLINIE, Pr · CHU Martinique
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-12-07
- Primary Completion
- 2019-10-19
- Completion
- 2019-12-31
Countries
- France
- Martinique
Study Locations
More Related Trials
-
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20)
NCT06459180 ·Status: RECRUITING ·Phase: PHASE3
-
A Multicenter, Prospective, Randomized Trial of Adjuvant Chemotherapy for Early-Stage Cervical Cancer Patients
NCT01755897 ·Status: COMPLETED ·Phase: NA
-
Pelvic RT Versus Prophylactic Extended-field RT in Patients With Cervical Cancer
NCT03955367 ·Status: UNKNOWN ·Phase: PHASE3
-
Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer
NCT05883670 ·Status: RECRUITING
-
HPV 16-positive and/or HPV 18-positive Recurrent and/or For Patients With Metastatic Head and Neck Cancer to Evaluate GX-188E DNA Vaccination, GX-I7 and Nivolumab Combination Therapy
NCT05280457 ·Status: RECRUITING ·Phase: PHASE2
-
Comparing Neoadjuvant Chemotherapy Combined With PD-1 Inhibitor Versus Neoadjuvant Chemotherapy in Locally Advanced Laryngeal and Hypopharyngeal Carcinoma
NCT06957938 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer
NCT03811015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Preoperative Chemoradiotherapy Combined With Nimotuzumab for Cervical Cancer
NCT01938105 ·Status: UNKNOWN ·Phase: PHASE2
-
Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab
NCT05075122 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer
NCT05179239 ·Status: TERMINATED ·Phase: PHASE3
-
Head and Neck Cancer Treatment Patterns and Outcomes Research Study in France, Germany, and Canada
NCT02705833 ·Status: COMPLETED
-
A Phase II Study to Evaluate the Efficacy and Safety of Salvage Preoperative PD-1 Inhibitor Combined with Chemotherapy Neoadjuvant Therapy in Recurrent and Metastatic LPSCC/HPSCC
NCT06793761 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma
NCT05328024 ·Status: RECRUITING
-
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT05798819 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Biomarker-Driven Radiation Therapy Dose Reduction After Transoral Robotic Surgery for the Treatment of HPV-Positive Oropharyngeal Cancer
NCT05387915 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Circulating Tumor Cells as an Early Predictive head-and -Neck Squamous-cell Carcinoma
NCT02119559 ·Status: UNKNOWN ·Phase: NA
-
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer
NCT04982237 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Chemotherapy and Pelvic Hypofractionated Radiation Followed by Brachytherapy for Cervical Cancer
NCT04070976 ·Status: RECRUITING ·Phase: NA
-
Comparing Two Surveillance Approaches for People Who Have Received Treatment for HPV-associated Head and Neck Cancer and Show No Signs of Disease
NCT05048459 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Efficacy and Safety of Immunotherapy Combined With Neoadjuvant Chemotherapy in Patients With Locally Advanced HPV (-) Head and Neck Squamous Cell Carcinoma: a Phase II Clinical Trial
NCT04929067 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of VB10.16 and Pembrolizumab in Patients with Head-Neck Squamous Cell Carcinoma
NCT06016920 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Comparing the Efficacy of Surgery Staging and Image Staging of Locally Advanced Cervical Cancer
NCT05378087 ·Status: RECRUITING ·Phase: NA
-
A Study of Nivolumab in Patients With Head and Neck Cancer.
NCT04050761 ·Status: COMPLETED
-
Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer
NCT06997094 ·Status: RECRUITING ·Phase: PHASE1
-
Tolerance and Efficacy of Pembrolizumab or Cetuximab Combined With RT in Patients With Locally Advanced HNSCC
NCT02707588 ·Status: COMPLETED ·Phase: PHASE2